# Aeglea BioTherapeutics Inc. (AGLE)

Source: https://www.quantisnow.com/company/AGLE
Generated: 2026-11-11T12:03:48.569Z

- Ticker: AGLE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2016
- Website: aeglea.com

## About

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

## Latest AGLE news and filings

- 2024-02-15 01:47 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5265772)
- 2024-02-14 21:51 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5264530)
- 2024-02-14 21:37 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5264207)
- 2024-02-14 21:27 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5263885)
- 2024-02-14 21:21 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5263699)
- 2024-02-14 21:05 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5263027)
- 2024-02-14 20:51 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5262649)
- 2024-02-14 19:07 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5261960)
- 2024-02-14 14:08 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-aeglea-biotherapeutics-inc-5259977)
- 2024-02-14 13:56 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5259829)
- 2024-02-14 12:02 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-aeglea-biotherapeutics-inc-5259244)
- 2024-02-13 23:46 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5258044)
- 2024-02-13 22:28 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5257714)
- 2024-02-13 21:48 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5255518)
- 2024-02-13 14:39 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5252990)
- 2024-02-12 17:03 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5249355)
- 2024-02-09 15:20 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-aeglea-biotherapeutics-inc-5245151)
- 2024-02-08 21:36 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-aeglea-biotherapeutics-inc-amendment-5242375)
- 2024-02-07 02:37 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-aeglea-biotherapeutics-inc-5235221)
- 2024-02-05 22:29 UTC [SEC Form 4] [SEC Form 4 filed by Mckenna Mark C.](https://www.quantisnow.com/insight/sec-form-4-filed-by-mckenna-mark-c-5230966)
- 2024-02-05 22:25 UTC [SEC Form 3] [SEC Form 3 filed by new insider Mckenna Mark C.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-mckenna-mark-c-5230927)
- 2024-02-05 12:36 UTC [SEC Form 8-K] [Aeglea BioTherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/aeglea-biotherapeutics-inc-filed-sec-form-8-k-entry-into-a-5228449)
- 2024-02-03 01:31 UTC [SEC Form 4] [SEC Form 4 filed by Turtle Cameron](https://www.quantisnow.com/insight/sec-form-4-filed-by-turtle-cameron-5227864)
- 2024-02-03 01:27 UTC [SEC Form 4] [SEC Form 4 filed by Burrows Scott L](https://www.quantisnow.com/insight/sec-form-4-filed-by-burrows-scott-l-5227861)
- 2024-02-03 01:23 UTC [SEC Form 4] [SEC Form 4 filed by King-Jones Heidy](https://www.quantisnow.com/insight/sec-form-4-filed-by-king-jones-heidy-5227856)
- 2024-01-18 21:26 UTC [SEC Form 8-K] [Aeglea BioTherapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/aeglea-biotherapeutics-inc-filed-sec-form-8-k-notice-of-delisting-5194243)
- 2023-12-29 22:00 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-aeglea-biotherapeutics-inc-amendment-5159269)
- 2023-12-29 22:00 UTC [SEC Form 4] [Fairmount Funds Management Llc disposed of 3,435,480 shares and acquired 812,076 shares (SEC Form 4)](https://www.quantisnow.com/insight/fairmount-funds-management-llc-disposed-of-3435480-shares-and-acquired-5159253)
- 2023-12-27 02:56 UTC [SEC Form D] [SEC Form D filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-aeglea-biotherapeutics-inc-5155459)
- 2023-12-22 23:00 UTC [SEC Form 4] [Burrows Scott L was granted 134,953 shares (SEC Form 4)](https://www.quantisnow.com/insight/burrows-scott-l-was-granted-134953-shares-sec-form-4-5153899)
- 2023-12-22 22:00 UTC [SEC Form S-8] [SEC Form S-8 filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-aeglea-biotherapeutics-inc-5153715)
- 2023-12-22 21:32 UTC [SEC Form S-1] [SEC Form S-1 filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-aeglea-biotherapeutics-inc-5153551)
- 2023-12-13 20:50 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-aeglea-biotherapeutics-inc-5135556)
- 2023-12-11 22:41 UTC [SEC Form 4] [SEC Form 4 filed by Fairmount Funds Management Llc](https://www.quantisnow.com/insight/sec-form-4-filed-by-fairmount-funds-management-llc-5130957)
- 2023-12-11 22:21 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Aeglea BioTherapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-aeglea-biotherapeutics-inc-amendment-5130875)
- 2023-12-08 21:07 UTC [SEC Form 4] [Albers Jeffrey W. converted options into 34,360 shares (SEC Form 4) (Amendment)](https://www.quantisnow.com/insight/albers-jeffrey-w-converted-options-into-34360-shares-sec-form-5127596)
- 2023-12-08 21:06 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-aeglea-biotherapeutics-inc-5127564)
- 2023-12-08 21:03 UTC [SEC Form 3] [SEC Form 3 filed by new insider Albers Jeffrey W. (Amendment)](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-albers-jeffrey-w-5127512)
- 2023-12-08 13:45 UTC [SEC Form 8-K] [Aeglea BioTherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aeglea-biotherapeutics-inc-filed-sec-form-8-k-entry-into-a-5126740)
- 2023-12-01 21:15 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Aeglea BioTherapeutics Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-aeglea-biotherapeutics-inc-5113974)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AGLE
- Earnings history: https://www.quantisnow.com/earnings/AGLE
- Dividend history: https://www.quantisnow.com/dividends/AGLE
- Insider transactions: https://www.quantisnow.com/insiders/AGLE
- Options chain: https://www.quantisnow.com/options/AGLE
- SEC 8-K filings only: https://www.quantisnow.com/company/AGLE/8-k
- RSS and alerts for AGLE: https://www.quantisnow.com/docs/rss-feeds.md